匹伐他汀钙治疗老年冠心病患者42例的疗效

Effect of pitavastatin calcium therapy in 42 aged patients with coronary heart disease

目的:观察匹伐他汀钙治疗老年冠心病患者的疗效及安全性。方法:入选82例口服辛伐他汀10～20mg至少一年的老年冠心病患者,入院后随机分为辛伐他汀组(40例:继续服用辛伐他汀)和匹伐他汀组(42例,改为每晚睡前口服匹伐他汀钙1～2mg),疗程为8周。分别于用药前、用药后2、4、8周检测两组肝功、血脂、磷酸肌酸激酶变化,并进行比较。结果:匹伐他汀钙组总胆固醇(TC)和低密度脂蛋白-胆固醇(LDL-C)水平的下降与辛伐他汀片10～20mg/d相当[TC(4.31±0.67)mmol/L比(4.32±0.65)mmol/L,LDL-C(2.15±0.56)mmol/L比(2.05±0.78)mmol/L],P均>0.05。不良反应较轻微,仅辛伐他汀组出现3例谷丙转氨酶、谷草转氨酶水平升高,在治疗4周时其值均明显高于匹伐他汀组(P<0.05)。结论:匹伐他汀钙对老年冠心病患者疗效及安全性均较好,对肝功损害较轻。

Objective： To observe therapeutic effects and safety of pitavastatin calcium therapy in aged patients with coronary heart disease （CHD）. Methods.. A total of 82 aged CHD patients, who had taken simvastatin 10-20mg at least one year, were enrolled and randomly divided into simvastatin group （n = 40, went on taking simvastatin） and pitavastatin group （n= 42, received pitavastatin 1 -2mg every night）. Therapeutic course was eight weeks. Liver function, blood lipids and creatine kinase were measured in both groups before, two, four and eight weeks after treatment. Results： Compared with simvastatin group, there were no significant difference in lowering levels of total cholesterol （TC） and low density lipoprotein-cholesterol （LDL-C） in pitavastatin group [TC （4. 31 ± 0.67） mmol/L vs. （4. 32 ± 0. 65） retool/L, LDL-C （2. 15± 0. 56） mmol/L vs. （2. 05 ± 0.78） mmol/L], P〉0.05 both. Adverse reactions were mild. Only alanine transaminase and aspartate transminase levels mildly increased in three cases of simvastatin group on 4：h week, and these levels were significantly higher than those of pitavastatin group （P 〈0. 05）. Conclusion： Pitavastatin is effective and safe in aged patients with coronary heart disease and its damage to liver is mild.